Belgium has created a similar fast-track process as in Germany even though that some differences exist. Anyway, core question with new processes is always how the rules are being interpreted and applied. So, how important are clinical studies and when are those required? What are the price levels and negotiations components of the process? Can companies with a successful track record in Germany also be successful in Belgium?
Dr. Stefan Walzer and the Belgian market access expert Katrien de Groote are discussing these and other aspects around digital healthcare in Belgium.
MAP – Market Access Podcast, is the first and only bi-weekly market access podcast provided by MArS. Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website
For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de
Episode 18 – May 15, 2022